Akari Therapeutics, PLC (AKTX)

Market Cap	32.86M
Revenue (ttm)	n/a
Net Income (ttm)	-18.10M
Shares Out	5.93B
EPS (ttm)	-0.41
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	21,084
Open	0.542
Previous Close	0.573
Day's Range	0.5 - 0.577
52-Week Range	0.381 - 1.7
Beta	1.28
Analysts	Buy
Price Target	n/a
Earnings Date	Dec 7, 2022

About AKTX

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.

• Industry: Pharmaceuticals
• CEO: Gur Roshwalb
• Employees: 9
• Stock Exchange: NASDAQ
• Ticker Symbol: AKTX

Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

No stock price forecast available yet.

Price Target

n/a

Analyst Consensus: Buy

Stock Forecasts